Bristol-Myers Squibb ends Opdivo trial early as endpoint met

American pharma company Bristol-Myers Squibb (NYSE: BMY) has ended the pivotal Phase III trial of Opdivo (nivolumab) in renal cell cancer early.

The Checkmate-025 trial is an open-label randomized Phase III study of Opdivo versus everolimus in previously-treated patients with advanced or metastatic renal cell carcinoma. It was stopped early because an assessment by the independent Data Monitoring Committee concluded that the study met its endpoint and demonstrated superior overall survival in patients receiving Opdivo compared to the control arm.

The company is working to ensure all eligible patients will be informed of the opportunity to continue or start treatment with Opdivo in an open-label extension.